TRIAMOLONE-FORTE INJECTION

Main information

  • Trade name:
  • TRIAMOLONE-FORTE INJECTION
  • Pharmaceutical form:
  • PARENTERAL LIQUID/SOLUTION/SUSPENSION
  • Units in package:
  • 10mL
  • Class:
  • Veterinary Medicine
  • Medicine domain:
  • Animals
  • Medicine type:
  • Allopathic drug

Documents

Localization

  • Available in:
  • TRIAMOLONE-FORTE INJECTION
    Australia
  • Language:
  • English

Therapeutic information

  • Therapeutic group:
  • CAT | DOG | HORSE | BITCH | CASTRATE | CAT - QUEEN | CAT - TOM | COLT | DONKEY | ENDURANCE HORSE | FILLY | FOAL | GELDING | HIGH
  • Therapeutic area:
  • corticosteroid
  • Therapeutic indications:
  • CORTICOSTEROID | ADVANCING PARTURITION | ALLERGIC REACTIONS | ANTIADRENAL SUPPRESSION | ANTI-INFLAMMATORY | ANTISHOCK | ARTHRITIS | BRONCHITIS | CATABOLIC COMPLICATIONS | CHRONIC BRONCHITIS | CORTICOSTEROIDS | CORTICOSTEROIDS AND RELATE | COUGHS | DERMATITIS | DERMATOLOGICAL DISORDERS | DERMATOSES | ECZEMA | GLUCOGENIC STEROID | JOINT DISEASE | KETOSIS | LOCOMOTIVE DISEASES | MUSCULO SKELETAL INFLAMMAT | ORTHOPAEDIC | PARTURIENT UDDER OEDEMA | PARTURITION | PRURITIS | RESPIRATORY TRACT DISEASES | RHEUMATIC DISEASES | STRESS | TOXAEMIA | WATER RETENTION
  • Product summary:
  • For the suppression of inflammation in dermatological disorders and arthritic conditions in dogs, cats and horses.See PRECAUTIONS on product leaflet

Other information

Status

  • Source:
  • Australian Pesticides and Veterinary Medicines Authority (APVMA)
  • Authorization status:
  • Registered and available
  • Authorization number:
  • 36222/0904
  • Authorization date:
  • 18-11-2004
  • Last update:
  • 15-06-2017

Patient Information leaflet: composition, indications, side effects, dosage, interactions, adverse reactions, pregnancy, lactation

15-6-2018

Compounded Products Containing Triamcinolone-Moxifloxacin by Guardian Pharmacy Services (Dallas, Texas): Alert to Health Professionals - Adverse Events Reported After Receiving Eye Injections

Compounded Products Containing Triamcinolone-Moxifloxacin by Guardian Pharmacy Services (Dallas, Texas): Alert to Health Professionals - Adverse Events Reported After Receiving Eye Injections

At least 43 patient reported adverse event after receiving eye injections of Guardian’s Pharmacy Services compounded triamcinolone-moxifloxacin product during cataract surgery. The patients reportedly experienced various symptoms, including vision impairment, poor night vision, loss of color perception, and significant reductions in best-corrected visual acuity and visual fields. FDA identified multiple substances in Guardian’s product, including poloxamer 407 and poloxamer 407 degradants. FDA prepared i...

FDA - U.S. Food and Drug Administration

There are no news related to this product.